Monte Rosa Therapeutics (GLUE) Total Non-Current Liabilities (2025 - 2026)
Monte Rosa Therapeutics (GLUE) recorded quarterly Total Non-Current Liabilities of $93.2 million in Q1 2026, down 6.05% quarter-over-quarter from $99.2 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Total Non-Current Liabilities (2025 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $93.2 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $93.2 million; the TTM figure through Mar 2026 stood at $93.2 million (changed N/A YoY), while the FY2025 annual figure was $99.2 million, changed N/A from the prior year.
- Total Non-Current Liabilities was $93.2 million for Q1 2026 at Monte Rosa Therapeutics, down from $99.2 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $101.2 million in Q3 2025 to a low of $93.2 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Monte Rosa Therapeutics | 1.83 Bn | 1.15 Bn | - | 93.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93.20 Mn |
| Dec 31, 2025 | 99.20 Mn |
| Sep 30, 2025 | 101.20 Mn |